Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is Manager of Event & Health Communications, working on communications for BIO’s events and health care policy issues. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He is currently finishing up a Master’s degree in communications at Georgetown University.

Latest Posts

Getting Ready for #RDD2015 (Rare Disease Day 2015)

RDD_white

Rare Disease Day is just around the corner on February 28th. R&D investment into rare disease research by venture capitalists was a major focus of BIO’s recent Venture Funding of Therapeutic Innovation between 2004-2013, available for download here. One of the more interesting findings in the study is the large increase of funding by venture capitalists for rare disease R&D over the past decade, as this chart illustrates: Over the last 10 years, there has Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Deal Structures: More Options for Companies

CEO2013_115x75_Thumbnail copy

By most measures, 2014 was a great year for the biotechnology industry. Venture capital deal values, , licensing values and volume were all up, as were big pharma M&A deals and asset swaps. What do these trends mean for dealmakers in 2015? Answering that question was the task of a panel at the 2015 BIO CEO & Investor Conference, Emerging Trends in Deal Structures. Moderated by Fenwick and West’s Effie Toshav, the panel included: Bruce Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Getting Ahead of Ebola and Other Infectious Threats—Overturning Assumptions

ebola

Ebola was one of the biggest stories of 2014 (with Ebola fighters named the TIME Person of the Year), and the epidemic has led to renewed interest from governments and philanthropies to tackle the problem of emerging infectious diseases. To discuss the lessons learned and new approaches being taken in light of the Ebola crisis, BIO hosted a panel today at the 17th Annual BIO CEO & Investor Conference here in New York, moderated by Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Forbes Asks: Should Economists Perform Surgery and Doctors Conduct Economic Policy?

TheHill

Over at Forbes, University of Chicago economist Tomas Philipson has an insightful post analyzing several of the arguments frequently made in recent debates about the price and value of innovative medicines. Philipson argues that physicians are often self-interested as buyers when complaining about drug prices, and often fail to understand the broader economic context in which drug pricing decisions must be made: “Just as you wouldn’t let a financial planner perform cancer surgery, we shouldn’t Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Measles Outbreak Shows Dangers of Vaccine Misinformation

Vaccination

On Sunday, Centers for Disease Control (CDC) Director Tom Friedan said that the U.S. could be faced with a “large outbreak” of measles, according to the Washington Post. The agency reported that 102 cases of measles were confirmed in 14 states in January. Hundreds of others are being monitored for possible exposure. The majority of the confirmed cases are among patients who have not been vaccinated, illustrating the danger posed to both individual and public Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,